Sanofi (SNYNF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 12:50PM EDT
| Previous Close | 101.50 |
| Open | 101.46 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 99.25 - 101.50 |
| 52 Week Range | 86.12 - 110.45 |
| Volume | |
| Avg. Volume | 26,198 |
| Market Cap | 125.037B |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | 25.58 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 4.06 (4.09%) |
| Ex-Dividend Date | May 13, 2024 |
| 1y Target Est | N/A |
- Reuters
UPDATE 2-Novavax signs COVID-19 license deal with Sanofi, removes doubt about business viability
Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with Sanofi for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker's market value. In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax's Matrix-M adjuvant.
- Thomson Reuters StreetEvents
Q1 2024 Royalty Pharma PLC Earnings Call
Q1 2024 Royalty Pharma PLC Earnings Call
- Zacks
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.
© 2024 Yahoo. All rights reserved.